Aripiprazole for relapse prevention in bipolar disorder: a 26-week placebo-controlled study

被引：0
|
作者：
Sanchez, R
McQuade, R
Marcus, R
Carson, W
Rollin, L
Iwamoto, T
Stock, E
机构：
[1] Bristol Myers Squibb, Pharmaceut Res Inst, Wallingford, CT 06492 USA
[2] Otsuka Amer Pharmaceut Inc, Princeton, NJ USA
[3] Bristol Myers Squibb, Wallingford, CT 06492 USA
[4] Otsuka Pharmaceut Co Ltd, Tokyo, Japan
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2005年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S511 / S512
页数：2
相关论文
共 50 条
  • [21] Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics
    Lee, Jung-Sun
    Chung, Seockhoon
    Lee, Joon-Noh
    Kwon, Jun Soo
    Kim, Do Hoon
    Kim, Chul Eung
    Oh, Kang Seob
    Jeon, Yang-Whan
    Lee, Min-Soo
    Lim, Myung Ho
    Chang, Hye-Ryein
    Kim, Chang Yoon
    PSYCHIATRY INVESTIGATION, 2010, 7 (03) : 189 - 195
  • [22] Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study
    Kwon, Jun Soo
    Jang, Joon Hwan
    Kang, Do-Hyung
    Yoo, So Young
    Kim, Yong Ku
    Cho, Seong-Jin
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2009, 63 (01) : 73 - 81
  • [23] The efficacy of topiramate in migraine prevention: Analyses of pooled data from three, 26-week, placebo-controlled, double-blind topiramate trials
    Bussone, G.
    D'Amico, D.
    Jacobs, D.
    Neto, W.
    Pfeill, J.
    Smuts, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 234 - 235
  • [24] The efficacy of topiramate in migraine prevention: analyses of pooled data from three, 26-week, placebo-controlled, double-blind topiramate trials
    Farkkila, M
    Bussone, G
    D'Amico, D
    Jacobs, D
    Neto, W
    Pfeil, J
    CEPHALALGIA, 2004, 24 (09) : 809 - 810
  • [25] Relapse prevention by citalopram in SAD patients responding to 1 week of light therapy. A placebo-controlled study
    Martiny, K
    Lunde, M
    Simonsen, C
    Clemmensen, L
    Poulsen, DL
    Solstad, K
    Bech, P
    ACTA PSYCHIATRICA SCANDINAVICA, 2004, 109 (03) : 230 - 234
  • [26] Double-Blind, Randomized, Placebo-Controlled Long-Term Maintenance Study of Aripiprazole in Children With Bipolar Disorder
    Findling, Robert L.
    Youngstrom, Eric A.
    McNamara, Nora K.
    Stansbrey, Robert J.
    Wynbrandt, Jaime L.
    Adegbite, Clara
    Rowles, Brieana M.
    Demeter, Christine A.
    Frazier, Thomas W.
    Calabrese, Joseph R.
    JOURNAL OF CLINICAL PSYCHIATRY, 2012, 73 (01) : 57 - 63
  • [27] Criteria for Defining Symptomatic and Sustained Remission in Bipolar I Disorder: a Post-Hoc Analysis of a 26-Week Aripiprazole Study (Study CN138-010)
    Masand, Prakash S.
    Eudicone, James
    Pikalov, Andrei
    McQuade, Robert D.
    Marcus, Ronald N.
    Vester-Blokland, Estelle
    Carlson, Berit X.
    PSYCHOPHARMACOLOGY BULLETIN, 2008, 41 (02) : 12 - 23
  • [28] Acamprosate and relapse prevention in the treatment of alcohol dependence: A placebo-controlled study
    Tempesta, E
    Janiri, L
    Bignamini, A
    Chabac, S
    Potgieter, A
    ALCOHOL AND ALCOHOLISM, 2000, 35 (02): : 202 - 209
  • [29] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF RISPERIDONE LONG-ACTING INJECTABLE IN RELAPSE PREVENTION IN PATIENTS WITH BIPOLAR I DISORDER
    Montgomery, S.
    Vieta, E.
    Sulaiman, A. H.
    Cordoba, R.
    Huberlant, B.
    Schreiner, A.
    Martinez, G.
    EUROPEAN PSYCHIATRY, 2010, 25
  • [30] Randomized, placebo-controlled, long-term study of risperidone long-acting injectable in relapse prevention in bipolar I disorder patients
    Quiroz, J. A.
    Yatham, L. N.
    Palumbo, J. M.
    Karcher, K.
    Kushner, S.
    Kusumakar, V.
    BIPOLAR DISORDERS, 2009, 11 : 71 - 71
12345